相关实验视频
Updated: Jun 10, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在糖尿病患者中查低血糖风险和药物变化,使用药房分发数据
Indriastuti Cahyaningsih1,2, Amal Asiri1,3, Stijn de Vos1
1Department of PharmacoTherapy, -Epidemiology, and -Economics, University of Groningen, 9713 AV Groningen, The Netherlands.
Journal of clinical medicine
|October 16, 2024
概括
许多糖尿病患者面临高低血糖风险,但很少有人接受治疗调整. 药房数据可以识别那些需要药物审查的人,以改善初级保健中的低血糖管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在初级保健中有效的低血糖管理需要更好的查风险患者.
- 常规可用的数据为识别低血糖风险和指导治疗修改提供了机会.
研究的目的:
- 使用药房发行数据量化糖尿病患者患低血糖高风险的数量.
- 描述高风险患者的治疗变化,并确定相关的患者特征.
主要方法:
- 一年期的药物使用队列研究,使用IADB.nl药房数据库.
- 包括35岁以上的患者,在2019年至少两次服用降血糖药物.
- 基于人口和发行数据的低血糖风险评分的验证算法;用于治疗变化分析的多项逻辑回归.
主要成果:
- 在36628名患者中,26.9%的患者患有高低血糖风险评分 (≥0.6).
- 88.9%的高风险患者在一年后没有改变糖尿病治疗.
- 减强发生在8.8%,加剧发生在2.3%;高风险,女性性别和年龄较小与减强有关.
结论:
- 在服用降血糖药物的初级保健患者中,有很大一部分患有低血糖症的风险.
- 在高风险患者中,降低药物强度是罕见的,这表明在护理方面存在差距.
- 药房发行数据是查糖尿病患者需要治疗审查的宝贵工具.
相关概念视频
Diabetes: Management and Pharmacotherapy
238
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
238
Hypoglycemia and Glucagon
164
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
Insulin: Dosing Regimen and Adverse Effects
152
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
152
Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178

